Skip to main content
. Author manuscript; available in PMC: 2024 Feb 15.
Published in final edited form as: Nat Cancer. 2023 Apr 10;4(5):699–715. doi: 10.1038/s43018-023-00539-6

Extended Data Fig. 9 |. Proposed model of PSMA regulation in prostate cancer.

Extended Data Fig. 9 |

PSMA (FOLH1) expression is activated in prostate cancer via binding of both AR and its cofactor HOXB13 to the PSMA enhancer. Even in the absence of AR expression, a subset of AR-negative tumors will still express PSMA due to HOXB13 binding of the PSMA enhancer. CRPC tumors may suppress or lose PSMA expression either due to loss of AR/HOXB13 binding of the PSMA promotor and/ or methylation of the PSMA promotor.